Dopamine receptors

Research output: Chapter in Book/Report/Conference proceedingChapter

2 Citations (Scopus)

Abstract

Beginning with the initial suggestion that antipsychotic neuroleptic drugs block dopamine receptors (1), and continuing with the demonstration that the affinity of antipsychotic drugs for dopamine receptors is highly correlated with clinical potency (2,3), and that the density of [3H]neuroleptic- labeled dopamine receptors is enhanced in postmortem brain tissue of schizophrenics (4), the study of dopamine receptors has been inextricably linked with hypotheses for the mechanism of action of antipsychotic drugs and the etiology of schizophrenia. As described in other chapters in this volume, the role of dopamine in numerous other neuropsychiatric disorders, such as parkinsonism, attention deficit hyperactivity disorder, and addiction, has made consideration of the properties of dopamine receptor subtypes important for attempts to provide improved pharmacological treatments for these disorders. This chapter summarizes the molecular cloning of the five mammalian dopamine receptor subtypes, and reviews their structural, pharmacological, signaling, and regulatory properties.

Original languageEnglish (US)
Title of host publicationDopamine and Glutamate in Psychiatric Disorders
PublisherHumana Press
Pages3-43
Number of pages41
ISBN (Print)9781588293251
DOIs
StatePublished - 2005
Externally publishedYes

Fingerprint

Dopamine Receptors
Antipsychotic Agents
Pharmacology
Drug Receptors
Parkinsonian Disorders
Molecular Cloning
Attention Deficit Disorder with Hyperactivity
Dopamine
Schizophrenia
Brain

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Neve, K. (2005). Dopamine receptors. In Dopamine and Glutamate in Psychiatric Disorders (pp. 3-43). Humana Press. https://doi.org/10.1007/978-1-59259-852-6_1

Dopamine receptors. / Neve, Kim.

Dopamine and Glutamate in Psychiatric Disorders. Humana Press, 2005. p. 3-43.

Research output: Chapter in Book/Report/Conference proceedingChapter

Neve, K 2005, Dopamine receptors. in Dopamine and Glutamate in Psychiatric Disorders. Humana Press, pp. 3-43. https://doi.org/10.1007/978-1-59259-852-6_1
Neve K. Dopamine receptors. In Dopamine and Glutamate in Psychiatric Disorders. Humana Press. 2005. p. 3-43 https://doi.org/10.1007/978-1-59259-852-6_1
Neve, Kim. / Dopamine receptors. Dopamine and Glutamate in Psychiatric Disorders. Humana Press, 2005. pp. 3-43
@inbook{6f41d6cd4f0440f1be35943288582592,
title = "Dopamine receptors",
abstract = "Beginning with the initial suggestion that antipsychotic neuroleptic drugs block dopamine receptors (1), and continuing with the demonstration that the affinity of antipsychotic drugs for dopamine receptors is highly correlated with clinical potency (2,3), and that the density of [3H]neuroleptic- labeled dopamine receptors is enhanced in postmortem brain tissue of schizophrenics (4), the study of dopamine receptors has been inextricably linked with hypotheses for the mechanism of action of antipsychotic drugs and the etiology of schizophrenia. As described in other chapters in this volume, the role of dopamine in numerous other neuropsychiatric disorders, such as parkinsonism, attention deficit hyperactivity disorder, and addiction, has made consideration of the properties of dopamine receptor subtypes important for attempts to provide improved pharmacological treatments for these disorders. This chapter summarizes the molecular cloning of the five mammalian dopamine receptor subtypes, and reviews their structural, pharmacological, signaling, and regulatory properties.",
author = "Kim Neve",
year = "2005",
doi = "10.1007/978-1-59259-852-6_1",
language = "English (US)",
isbn = "9781588293251",
pages = "3--43",
booktitle = "Dopamine and Glutamate in Psychiatric Disorders",
publisher = "Humana Press",

}

TY - CHAP

T1 - Dopamine receptors

AU - Neve, Kim

PY - 2005

Y1 - 2005

N2 - Beginning with the initial suggestion that antipsychotic neuroleptic drugs block dopamine receptors (1), and continuing with the demonstration that the affinity of antipsychotic drugs for dopamine receptors is highly correlated with clinical potency (2,3), and that the density of [3H]neuroleptic- labeled dopamine receptors is enhanced in postmortem brain tissue of schizophrenics (4), the study of dopamine receptors has been inextricably linked with hypotheses for the mechanism of action of antipsychotic drugs and the etiology of schizophrenia. As described in other chapters in this volume, the role of dopamine in numerous other neuropsychiatric disorders, such as parkinsonism, attention deficit hyperactivity disorder, and addiction, has made consideration of the properties of dopamine receptor subtypes important for attempts to provide improved pharmacological treatments for these disorders. This chapter summarizes the molecular cloning of the five mammalian dopamine receptor subtypes, and reviews their structural, pharmacological, signaling, and regulatory properties.

AB - Beginning with the initial suggestion that antipsychotic neuroleptic drugs block dopamine receptors (1), and continuing with the demonstration that the affinity of antipsychotic drugs for dopamine receptors is highly correlated with clinical potency (2,3), and that the density of [3H]neuroleptic- labeled dopamine receptors is enhanced in postmortem brain tissue of schizophrenics (4), the study of dopamine receptors has been inextricably linked with hypotheses for the mechanism of action of antipsychotic drugs and the etiology of schizophrenia. As described in other chapters in this volume, the role of dopamine in numerous other neuropsychiatric disorders, such as parkinsonism, attention deficit hyperactivity disorder, and addiction, has made consideration of the properties of dopamine receptor subtypes important for attempts to provide improved pharmacological treatments for these disorders. This chapter summarizes the molecular cloning of the five mammalian dopamine receptor subtypes, and reviews their structural, pharmacological, signaling, and regulatory properties.

UR - http://www.scopus.com/inward/record.url?scp=34147218410&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34147218410&partnerID=8YFLogxK

U2 - 10.1007/978-1-59259-852-6_1

DO - 10.1007/978-1-59259-852-6_1

M3 - Chapter

AN - SCOPUS:34147218410

SN - 9781588293251

SP - 3

EP - 43

BT - Dopamine and Glutamate in Psychiatric Disorders

PB - Humana Press

ER -